Neurite outgrowth mediated by translation elongation factor eEF1A1: A target for antiplatelet agent cilostazol

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Hashimoto, Kenji ^a   Ishima, Tamaki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE; CILOSTAZOL; ELONGATION FACTOR; EUKARYOTIC ELONGATION FACTOR 1A1 PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; ELONGATION FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE A; QUINOLONE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; NERVE FIBER GROWTH; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEOMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; CELL STRAIN; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; NEURITE; RAT;

EUKARYOTA;

ANIMALS; DRUG SYNERGISM; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MILRINONE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NERVE GROWTH FACTOR; NEURITES; PC12 CELLS; PEPTIDE ELONGATION FACTOR 1; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHOLIPASE C GAMMA; PLATELET AGGREGATION INHIBITORS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLONES; RAF KINASES; RAS PROTEINS; RATS; RECEPTOR, TRKA; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 79952285928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017431     Document Type: Article

References (41)

1. Chapman TM, Goa KL, (2003) Cilostazol: a review of its use in intermittent claudication. Am J Cardiovas Drugs 3: 117-138.
2. Hiatt WR, (2006) The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl 6 pp. 21-31.
3. Liao JK, (2007) Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation 115: 1615-1621.
4. Hankey GJ, Eikelboom JW, (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 9: 273-284.
5. Gotoh F, Tohgi H, Hirai S, Teranishi A, Fukuuchi Y, et al. (2000) Cilostazol stroke prevention study: a placebo-controlled trial for secondary prevention of cerebral ischemia. J Stroke Cerebrovasc Dis 9: 147-157.
6. Matsumoto M, (2006) Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl. 6 pp. 33-40.
7. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, et al. (2008) Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovas Dis 26: 63-70.
8. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, et al. (2009) Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 18: 482-490.
9. Huang Y, Cheng Y, Wu J, Li Y, Xu E, et al. (2008) Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 7: 494-499.
10. Hankey GJ, (2008) Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke. Lancet Neurol 7: 469-470.
11. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, et al. (2005) Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36: 782-786.
12. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, et al. (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968.
13. Hashimoto K, Fujita Y, Ishima T, Horio M, Hagiwara H, et al. (2010) Effects of cilostazol on cognitive deficits in mice after repeated administration of phencyclidine. Clin Psychopharmacol Neurosci 8: 26-29.
14. Hashimoto K, Fujita Y, Horio M, Hagiwara H, Tanibuchi Y, et al. (2010) Effects of cilostazol on dizocilpine-induced hyperlocomotion and prepulse inhibition deficits in mice. Clin Psychopharmacol Neurosci 8: 74-78.
15. Baba H, Kubota Y, Suzuki T, Arai H, (2007) Seven cases of late-life depression treated with cilostazol-augmented therapy. J Clin Psychopharmacol 27: 727-728.
16. Takahashi K, Oshima A, Inoue K, Takeyoshi H, Fukuda M, et al. (2008) Novel augmentation therapy with cilostazol for the geriatric major depressive disorder patient with deep white matter hyperintensities on T2-weighted brain MRI: a case report. Pharmacotherapy 41: 37-39.
17. Arai H, Takahashi T, (2009) A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 17: 353-354.
18. Lakics V, Karran EH, Boess FG, (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59: 367-374.
19. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, et al. (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59: 347-356.
20. Nishimura T, Ishima T, Iyo M, Hashimoto K, (2008) Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 3: e2558.
21. Ishima T, Nishimura T, Iyo M, Hashimoto K, (2008) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 32: 1656-1659.
22. Minase T, Ishima T, Itoh K, Hashimoto K, (2010) Potentaition of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: a potential role of IP3 receptors. Eur J Pharmacol 648: 67-73.
23. Hashimoto K, Ishima T, (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI. PLoS One 5: e15430.
24. Mateyak MK, Kinzy TG, (2010) eEF1A: thinking outside the ribosome. J Biol Chem 285: 21209-21013.
25. Huang EJ, Reichardt LF, (2001) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642.
26. Chao MV, (2003) Neurotrophins and their receptors: a convergence point for many signaling pathways. Nature Rev Neurosci 4: 299-309.
27. Read DE, Gorman AM, (2009) Involvement of Akt in neurite outgrowth. Cell Mol Life Sci 66: 2975-2984.
28. Gafni J, Munsch JA, Lam TH, Catlin MC, Costa LG, et al. (1997) Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 19: 723-733.
29. Sofroniew MV, Howe CL, Mobley WC, (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-1281.
30. Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, et al. (1994) Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses. Neuron 12: 691-705.
31. Kimura K, Hattori S, Kabuyama Y, Shizawa Y, Takayanagi J, et al. (1994) Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 269: 18961-18967.
32. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N, (2009) Translational control of long-lasting synaptic plasticity and memory. Neuron 61: 10-26.
33. Berridge MJ, (1993) Inositol trisphosphate and calcium signaling. Nature 361: 315-325.
34. Iketani M, Imaizumi C, Nakamura F, Jeromin A, Mikoshiba K, et al. (2009) Regulation of neurite outgrowth mediated by neuronal calcium sensor-1 and inositol 1,4,5-trisphosphate receptor in nerve growth cones. Neuroscience 161: 743-752.
35. Takei K, Shin RM, Inoue T, Kato K, Mikoshiba K, (1998) Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Science 282: 1705-1708.
36. Kapp LD, Lorsch JR, (2004) The molecular mechanisms of eukaryotic translation. Annu Rev Biochem 73: 657-704.
37. Jackson RJ, hellen CUT, Pestova TV, (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. Nature Rev Mol Cell Biol 10: 113-127.
38. Duttaroy A, Bourbeau D, Wang XL, Wang E, (1998) Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1α. Exp Cell Res 238: 168-176.
39. Talapatra S, Wagner JD, Thompson CB, (2002) Elongation factor-1 α is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ 9: 856-861.
40. Fujii DK, Massoglia SL, Savion N, Gospodarowicz D, (1982) Neurite outgrowth and protein synthesis by PC12 cells as a function of substratum and nerve growth factor. J Neurosci 2: 1157-1175.
41. Sun B, Li H, Shakur Y, Hensley J, Hockman S, et al. (2007) Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 19: 1765-1771.